Erratum: Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo

被引：0
|
作者：
Jason J. Zoeller
Roderick T. Bronson
Laura M. Selfors
Gordon B. Mills
Joan S. Brugge
机构：
[1] Harvard Medical School,Department of Cell Biology
[2] Harvard Medical School,Rodent Histopathology Core
[3] UT MD Anderson Cancer Center,Systems Biology
来源：
npj Breast Cancer | / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A correction to this article has been published and is linked from the HTML version of this article.
引用
收藏
相关论文
共 11 条
  • [1] Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo
    Zoeller, Jason J.
    Bronson, Roderick T.
    Selfors, Laura M.
    Mills, Gordon B.
    Brugge, Joan S.
    NPJ BREAST CANCER, 2017, 3
  • [2] Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo
    Jason J. Zoeller
    Roderick T. Bronson
    Laura M. Selfors
    Gordon B. Mills
    Joan S. Brugge
    npj Breast Cancer, 3
  • [3] Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo (vol 3, 18, 2017)
    Zoeller, Jason J.
    Bronson, Roderick T.
    Selfors, Laura M.
    Mills, Gordon B.
    Brugge, Joan S.
    NPJ BREAST CANCER, 2017, 3
  • [4] Basement membrane localized tumor cells are protected from HER2-targeted therapy in vivo
    Zoeller, Jason J.
    Bronson, Roderick T.
    Gilmer, Tona M.
    Selfors, Laura M.
    Lu, Yiling
    Mills, Gordon B.
    Brugge, Joan S.
    CANCER RESEARCH, 2012, 72
  • [5] Basement membrane localized tumor cells are protected from HER2-targeted therapy in vivo.
    Zoeller, J. J.
    Bronson, R. T.
    Gilmer, T. M.
    Selfors, L. M.
    Lu, Y.
    Apple, S. K.
    Press, M. F.
    Hurvitz, S. A.
    Slamon, D. J.
    Mills, G. B.
    Brugge, J. S.
    CANCER RESEARCH, 2012, 72
  • [6] Basement Membrane Localized Tumor Cells Are Protected from HER2-Targeted Therapy In Vivo.
    Zoeller, J. J.
    Bronson, R. T.
    Gilmer, T. M.
    Selfors, L. M.
    Lu, Y.
    Mills, G. B.
    Brugge, J. S.
    CANCER RESEARCH, 2011, 71
  • [7] Basement membrane-localized tumor cells are protected from HER2-targeted therapy in vivo
    Zoeller, Jason
    Bronson, Roderick
    Gilmer, Tona
    Selfors, Laura
    Lu, Yiling
    Apple, Sophia
    Press, Michael
    Hurvitz, Sara
    Slamon, Dennis
    Mills, Gordon
    Brugge, Joan
    GLYCOBIOLOGY, 2012, 22 (11) : 1531 - 1532
  • [8] PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling
    S E Moody
    A C Schinzel
    S Singh
    F Izzo
    M R Strickland
    L Luo
    S R Thomas
    J S Boehm
    S Y Kim
    Z C Wang
    W C Hahn
    Oncogene, 2015, 34 : 2061 - 2071
  • [9] PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling
    Moody, S. E.
    Schinzel, A. C.
    Singh, S.
    Izzo, F.
    Strickland, M. R.
    Luo, L.
    Thomas, S. R.
    Boehm, J. S.
    Kim, S. Y.
    Wang, Z. C.
    Hahn, W. C.
    ONCOGENE, 2015, 34 (16) : 2061 - 2071
  • [10] TLR2 agonist PSK activates NK cells and enhances the anti-tumor effect of HER2-targeted monoclonal antibody therapy
    Lu, Hailing
    Yang, Yi
    Gad, Ekram
    Disis, Mary L.
    CANCER RESEARCH, 2011, 71
12